Advanced Life Sciences to Host 2010 Fourth Quarter and Full-Year Financial Results Conference Call and Webcast

CHICAGO, March 17, 2011 /PRNewswire/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that it will host a conference call and webcast discussing the Company's 2010 fourth quarter and full-year financial results on Thursday, March 24, 2011 at 9:00 AM (EDT). Michael T. Flavin, Ph.D., Chairman & Chief Executive Officer, as well as other members of the management team, will also present an update on the Company. A press release reporting the 2010 fourth quarter and full-year results will be issued before the U.S. stock markets open on Thursday, March 24, 2011.

(Logo:  http://photos.prnewswire.com/prnh/20080218/ALSLOGO)

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-713-4211 (domestic) or 617-213-4864 (international). The passcode for the conference call is 86880056. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PAVMV3UD3.

Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

A replay of the conference call will be available until March 31, 2011. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75965641.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

SOURCE Advanced Life Sciences Holdings, Inc.

Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.